View live charts, options flow & technicals for The Cooper Companies, Inc. →
Open Dashboard
The Cooper Companies, Inc. (COO) is a healthcare company in the medical instruments & supplies industry with $4.24B in trailing revenue trading at a 19.0× trailing P/E — analyst consensus: buy.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Key Statistics
Market Cap
$10.53B
Revenue (TTM)
$4.24B
EPS (TTM)
$2.91
EPS (Fwd est.)
$4.69
Employees
15,000
Trailing P/E
19.03
Forward P/E
11.80
PEG Ratio
0.52
Price / Sales
2.49
Price / Book
1.26
EV / EBITDA
14.14
Beta (5Y)
0.82
Analyst Consensus
Consensus
Buy
Analyst Price Target
+19.6% upside
Target: $66.21
Annual Revenue & Net Income
RevenueNet Income
'22
$3.31B
$390.00M
'23
$3.59B
$290.00M
'24
$3.90B
$390.00M
'25
$4.09B
$370.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Sep 2026
$1.15
$1.12
Beat (+2.7%)
Jun 2026
$1.21
$1.09
Beat (+10.5%)
Mar 2026
$1.10
$1.03
Beat (+7.0%)
Dec 2025
$1.15
$1.11
Beat (+3.3%)
Next Earnings Report
The Cooper Companies, Inc. is next expected to report earnings on 09 Sep 2026.
Profitability
65.9%
20.8%
13.5%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
0.6%
Return on Equity
6.8%
Return on Assets
2.7%
Balance Sheet
Cash & Equivalents
$150.00M
Total Debt
$2.80B
Net Position
$2.65B (net debt)
Free Cash Flow (TTM)
$540.00M
Debt / Equity
33.63
Share Ownership
Institutions 111.9%
Insiders 0.6%
Institutional figure exceeds 100% due to short selling
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women…
What is COO's market cap?
The Cooper Companies, Inc. has a market capitalization of approximately $10.53B.
What is COO's P/E ratio?
The Cooper Companies, Inc. trades at a trailing P/E ratio of 19.0x and a forward P/E of 11.8x, which is below the broad market average of ~25x.
How much revenue does COO generate?
The Cooper Companies, Inc. generated $4.24B in trailing 12-month revenue.
What do analysts say about COO?
The analyst consensus rating for The Cooper Companies, Inc. is buy, with a mean price target of $66.21. That implies +19.6% upside from the current price.
When does COO report earnings?
The Cooper Companies, Inc. is next scheduled to report earnings on 09 Sep 2026.
Does COO pay a dividend?
The Cooper Companies, Inc. does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for The Cooper Companies, Inc. on Apsis Markets.
